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a panel of Spanish oncologists and from the literature. Unit costs
were derived from Spanish databases (€ March 2006). Annual
discount rate: 3.5% (costs and utilities). Sensitivity analyses for
subpopulations, 3 years results (Weibull and Loglogistic distrib-
utions) and probabilistic (Monte Carlo) were performed.
RESULTS: After 2 years more QALY per patient were obtained
with ERL (0.24) than with DOC (0.23) and BSC (0.18). No dif-
ferences versus PEM were observed. The total cost per patient
was lower with ERL (€17,838) than with DOC (€20,392; 
€−2554) or PEM (€27,317; €−9479) and higher than with BSC
(€8198; €+9640). ERL was the “dominant” treatment (more efﬁ-
cacy and lower costs) versus DOC and resulted in a cost saving
versus PEM. Additional cost per QALY or life year gained with
ERL versus BSC: €160,667 and €56,706, respectively. The 
sensitivity analysis conﬁrmed the robustness of the base case
analysis. If 1000 NSCLC patients were treated with ERL, the
annual saving for NHS (substitution rates: 5%–65%) would
range between €123,000–€1,600,000 (DOC replacement) and
€448,000–€5,831,000 (PEM replacement). CONCLUSIONS:
According to this model, advanced NSCLC treatment with ERL
is more cost-effective than with DOC and PEM, with savings for
the NHS.
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OBJECTIVES: Chronic cancer pain has a devastating impact on
quality of life. This leads to an increase in heathcare services uti-
lization. The objective of the present study is to estimate the cost-
efectiveness and cost-utility quotients of Fentanyl TTS treatment
related to SR oral Morphine or IR oral Morphine in patients
with moderate-severe chronic cancer pain. METHODS:
Designed from the perspective of the health care provider, with
a 12 weeks horizon and a pharmacoeconomic decision making
model (decision tree). Cost-effectiveness relationship estimates
was $15 per day of pain control (DPC) for Fentanyl TTS , $.3
per DPC for sustained-release Morphine and $6.4 per DPC for
immediate release Morphine. Cost-utility relationship estimates
was $23.1 per Quality Adjusted DPC (QALD) for Fentanyl TTS,
$18.9 per QALD for sustained-release Morphine and $53.6 per
QALD for immediate realease Morphine. This means that the
cost of a QALD when treating patients with Fentanyl TTS is
similar that patients treated with SR Morphine and less than half
of patients treated with IR Morphine. RESULTS: The incre-
mental cost-effectiveness relationship (ICER) for Fentanyl TTS
vs. SR Morphine was of $20,2 per extra DPC, while the ICER
for Fentanyl TTS vs. IR Morphine was $26.1 per extra QALD.
The incremental cost-utility relationship (ICUR) for Fentanyl
TTS vs. Sustained-release Morphine was $24.9 per extra QALD
and of $19.2 per extra QALD for Fentanyl TTS vs. IR Morphine.
The pharmacoeconomic model constructed for the analysis was
duly validated through a one way sensitivity analysis. 
CONCLUSIONS: We concluded, compared to oral Morphines,
Femtanyl TTS is a cost-effective choice for the treatment of mod-
erate-severe cancer pain. The present analysis allows to draw the
conclusion that the better efﬁciency of this new transdermal
pharmaceutical form of Fentanyl, is mainly due to an improve-
ment in qualtiy of life.
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OBJECTIVE: Dacarbazine is routinely used as the ﬁrst line treat-
ment of disseminated malignant melanoma with brain metas-
tases in Poland. A head-to-head randomized controlled trial
(RCT) showed a clinical superiority of fotemustine over dacar-
bazine in this indication. At the same time patients’ access to
many innovative medicines in Poland is limited because of bud-
getary constraints. Even if an innovative medicine is more effec-
tive and cost-effective, it is not applied since it is more expensive
for the health care budget. The main objective of this analysis is
to verify whether an administration of fotemustine is econom-
icly justiﬁed for the National Health Fund (NHF)—the public
payer in Poland. METHODS: A cost-minimization analysis was
carried out from the NHF point of view. Direct medical costs
were divided according to accounting standards into two groups:
cost of drugs and cost of hospitalization required in order to
administer the drugs. The majority of unit prices used in calcu-
lations were derived from the ofﬁcial price list of the Pomeran-
ian Sickness Fund (which is the NHF part now). Following
clinical standards and the length of the RCT the time horizon is
26 weeks. RESULTS: The cost of fotemustine administered to
one patient (€4700) is higher than the cost of dacarbazine (€676)
by €4024. The cost of hospitalization necessary to administer
dacarbazine amounts to €5884 and is higher than cost for fote-
mustine (€1284) by €4600. The total cost in fotemustine group
amounts to €598 and was lower than cost of dacarbazine
(€6560) by €576. CONCLUSION: Substitution of dacarbazine
with fotemustine in the treatment of disseminated malignant
melanoma with brain metastases is a good alternative not only
for Polish patients (as clinically better) but also for the Polish
NHF (as cost–saving). Ex. rate 1 € = 3.98 PLN.
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OBJECTIVES: Oxaliplatin solution form is a new and safer for-
mulation of oxaliplatin avoiding the reconstitution step during
cytotoxic preparation. The main objective was to assess the eco-
nomic impact using oxaliplatin concentrated solution compared
with the lyophilised powder form from the hospital pharmacy
point of view. METHODS: Due to the equivalent efﬁcacy
between the 2 formulations, a cost-minimisation analysis with a
hospital perspective was performed comparing the solution
versus the powder. A single-centre observational study was con-
ducted in a French Cancer Centre. The cytotoxic preparations
were assessed using the powder in a ﬁrst time and the solution
form in a second time. The same staff member manipulated both
preparations in order to avoid any bias. Two independent
observers collected the results from the 30 manipulations. The
ﬁrst endpoint assessed was preparation time. Secondary endpoint
was overall cost associated with this preparation, which included
costs associated to preparation time, material and cytotoxic
waste management. RESULTS: The reconstitution step was
avoided using the solution form. The time saved with the solu-
tion form versus the lyophilised powder was 139 seconds per
preparation. The overall avoided cost represented €1.04 per
preparation using oxaliplatin solution form. This total cost could
